Lupus is like the Black Knight in Monty Python and the Holy Grail: it's been telling drug developers for decades that "none shall pass" -- and when they insist on trying to cross that Phase III bridge ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Dendreon Corporation (NASDAQ: DNDN) is living up to ...

MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...

GlaxoSmithKline (NYSE:GSK) and drug partner Human Genome Sciences (NASDAQ:HGSI) have started clinical trials on a different version of lupus drug Benlysta that would be easier to administer to ...

Jan. 21, 2011, 7:15 PM EST / Source: GlobeNewswire NEW YORK, Jan. 21, 2011 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of ...

This morning, Citigroup (C) lowered its price target on shares of Human Genome Sciences (HGSI) to $15 as sales of Benlysta have been lighter than originally expected. In the report, Citigroup reduced ...

Human Genome Sciences ( HGSI) and GlaxoSmithKline plc ( GSK) recently announced a definitive agreement under which the latter will acquire the former for $14.25 per share in cash. With this ...

Green Dot (GDOT) was downgraded today by Morgan Stanley (MS) to equal weight from overweight with a price target of $25 due to competitive and regulatory pressures currently facing the company. Shares ...

Active traders and day traders have many stocks to choose from this Thursday morning. We are tracking news and moves in shares of Clean Energy Fuels Corp. (NASDAQ: CLNE), Human Genome Sciences (NASDAQ ...